Listen on the go
CORRECT!
Next question
touchENDOCRINOLOGY touchENDOCRINOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Carol Levy, DTM 2022: Benefits of insulin pump in people living with type 2 diabetes
CONFERENCE HUB
Start Learning
Part 3. Bitter Sweet: ‘If It Wasn’t for You’
CONFERENCE HUB
Start Learning
Jennifer Clements, ADCES 2022: Clinical implications of SGLT-2 inhibitors for chronic kidney disease in people with type 2 diabetes
JOURNALS
Start Learning
Is Type 2 Diabetes Mellitus a Behavioural Disorder? An Evidence Review for Type 2 Diabetes Mellitus Prevention and Remission through Lifestyle Modification
CONFERENCE HUB
Start Learning
Silva Arslanian, ADA 2022: Dulaglutide for type 2 diabetes in youth, the AWARDS-PEDS study
Dr Hamdy ADA thumbnail
CONFERENCE HUB
Start Learning
Osama Hamdy, ADA 2022: Phenotypes and target options in diabetes
JOURNALS
Start Learning
APOC3 Interference for Familial Chylomicronaemia Syndrome
CONFERENCE HUB
Start Learning
Viktor Rotbain Curovic, EASD 2022: The challenges of treating patients at risk for diabetic kidney disease
Dr Riccardo Candido thumbnail
CONFERENCE HUB
Start Learning
Riccardo Candido, ADA 2022: GLP1-RA therapy for type 2 diabetes and the intensification strategies following treatment failure
Dr Dagogo-Jack ADA thumbnail
CONFERENCE HUB
Start Learning
Samuel Dagogo-Jack, ADA 2022: A study highlighting the association of sphingolipids with prediabetes risk – potential biomarkers?

to view Favourites, Keep Notes and Track CME Credits

Favourites
Andrea R. Genazzani, WCO IOF-ESCEO 2022: Hormone Replacement Therapy for Bone Loss Prevention Post Menopause (Part 1)
View
Samuel Dagogo-Jack, ADA 2022: Sphingolipids as a biomarker of prediabetes risk – what are the next steps?
View
Integrating GLP-1 RAs into T2D management: A unified approach, from PCP to patient
View
Peter Rossing, EASD 2022: The effect of semaglutide on risk of MACE by baseline kidney function: SUSTAIN 6 and PIONEER 6 post hoc analysis
View
Multidisciplinary insights on the role of GLP-1 RAs in the modern management of stroke in patients with T2D
View
Sara (Mandy) Reece, ADCES 2022: Chronic kidney disease in type 2 diabetes: An update for the diabetes care and education specialist
View
Kristien Boelaert, ATA 2022: The EGRET study: Long term mortality and cardiometabolic effects of hyperthyroidism treatment
View
Thyrotoxic Cardiomyopathy: State of the Art
View
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
View
Jennifer Clements, ADCES 2022: Efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients with diabetes
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72